Furthermore, intravenous administration of such EVs reduced both α-syn mRNA and protein levels in transgenic mice expressing the phosphomimetic human S129D alpha-synuclein, reduced the loss of dopaminergic neurons, and alleviated PD symptoms, implying the therapeutic benefits of such EVs to treat PD [88]. This evidence concerns the gene SNCA and Parkinson disease.